MARKET

ALDX

ALDX

Aldeyra
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.040
-0.080
-3.77%
After Hours: 2.025 -0.015 -0.74% 16:00 04/02 EDT
OPEN
2.100
PREV CLOSE
2.120
HIGH
2.180
LOW
2.005
VOLUME
190.62K
TURNOVER
--
52 WEEK HIGH
9.11
52 WEEK LOW
1.480
MARKET CAP
60.51M
P/E (TTM)
-0.9117
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ALDX stock price target is 29.00 with a high estimate of 34.00 and a low estimate of 24.00.

EPS

ALDX News

More
  • Edited Transcript of ALDX earnings conference call or presentation 12-Mar-20 12:00pm GMT
  • Thomson Reuters StreetEvents · 2d ago
  • What Makes Aldeyra Therapeutics, Inc. (ALDX) a New Buy Stock
  • Zacks · 03/24 17:00
  • Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection
  • Business Wire · 03/24 13:00
  • Coronavirus activity roundup - healthcare
  • Seeking Alpha - Article · 03/24 12:15

Industry

Biotechnology & Medical Research
+3.33%
Pharmaceuticals & Medical Research
+2.79%

Hot Stocks

Symbol
Price
%Change

About ALDX

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.
More

Webull offers kinds of Aldeyra Therapeutics Inc stock information, including NASDAQ:ALDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALDX stock news, and many more online research tools to help you make informed decisions.